According to the recommendations of the International Ki67 in Breast Cancer Working Group, the validity of Ki67 immunohistochemistry as a prognostic marker in the clinical practice of breast cancer has been verified, especially for the identification of oestrogen receptor‐positive and HER2‐negative patients who do not need neoadjuvant therapy.6 This evidence concerns the gene ERBB2 and breast cancer.